,34 Various studies, including our own, have established that MDM2 possesses both p53-dependent and -independent oncogenic activities32,35, 36, 37, 38, 39, 40, 41, 42, 43 and thus represents a promising target for cancer therapy and other chronic diseases,44, 45, 46, 47, 48, 49, 50, 51, 52, 53 with many MDM2 inhibitors currently in preclinical and clinical development.28 The gene discussed is TP53; the disease is cancer.